2016
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016. Journal Of Thoracic Oncology 2016, 11: 946-963. PMID: 27229180, DOI: 10.1016/j.jtho.2016.05.008.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerTyrosine kinase inhibitorsEGFR tyrosine kinase inhibitorsCell lung cancerLung cancerEpidermal growth factor receptor (EGFR) geneTreatment optionsConsensus statementEGFR-mutant non-small cell lung cancerEGFR Mutation-Positive NonFirst-line treatment optionSmall cell lung cancerThird-generation EGFR-TKI osimertinibCancer consensus statementLocal treatment optionsNew clinical algorithmEGFR-TKI osimertinibHigh response rateBrain metastasesRepeat biopsyClinical profileGrowth factor receptor geneClinical algorithmClinical guidelinesTreatment paradigm
2005
Therapeutic Strategies for Combined-Modality Therapy of Locally Advanced-Stage Non–Small-Cell Lung Cancer: Rationale for Consolidation Docetaxel Therapy
Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. Therapeutic Strategies for Combined-Modality Therapy of Locally Advanced-Stage Non–Small-Cell Lung Cancer: Rationale for Consolidation Docetaxel Therapy. Clinical Lung Cancer 2005, 7: s93-s97. PMID: 16384543, DOI: 10.3816/clc.2005.s.017.Peer-Reviewed Original ResearchConceptsCell lung cancerRadiation therapyDocetaxel therapyLung cancerChemotherapy/radiation therapyGood performance statusCombined modality therapyThoracic radiation therapyRecent clinical trialsStandard of careCombination of chemotherapyPerformance statusDose scheduleTreatment paradigmClinical trialsTherapeutic strategiesTherapyCancerChemotherapyPatientsTrialsCare